Claims
- 1. A compound of the formula:
- 2. A compound according to claim 1, wherein RA1 and RA4 are both —H; RB5 and RB7 are both —H; RC9 and RC12 are both —H; and wherein the compound has the following formula:
- 3. A compound according to claim 2, wherein:
RA1, RA2, RA3, and RA4 are all —H; RB5, RB6, and RB7 are all —H; and, RC9, RC10, RC11, and RC12 are all —H; (8,13-disubstituted); or RA1, RA2, and RA4 are all —H; RB5, RB6, and RB7 are all —H; RC9, RC10, RC11, and RC12 are all —H; and, RA3 is not —H; (3,8,13-trisubstituted); or RA1, RA2, RA3, and RA4 are all —H; RB5 and RB7 are both —H; RC9, RC10, RC11, and RC12 are all —H; and, RB6 is not —H; (6,8,13-trisubstituted); or RA1, RA2, RA3, and RA4 are all —H; RB5, RB6, and RB7 are all —H; RC9, RC11, and RC12 are all —H; and, RC10 is not —H; (8,10,13-trisubstituted); or RA1, RA2, and RA4 are all —H; RB5 and RB7 are both —H; RC9, RC10, RC11, and RC12 are all —H; and, RA3 and RB6 are both not —H; (3,6,8,13-tetrasubstituted); or RA1, RA2, and RA4 are all —H; RB5, RB6, and RB7 are all —H; RC9, RC11, and RC12 are all —H; and, RA3 and RC10 are both not —H; (3,8,10,13-tetrasubstituted); or RA1, RA2, RA3, and RA4 are all —H; RB5 and RB7 are both —H; RC9, RC11, and RC12 are all —H; and, RB6 and RC10 are both not —H; (6,8,10,13-tetrasubstituted); or RA1, RA2, and RA4 are all —H; RB5 and RB7 are both —H; RC9, RC11, and RC12 are all —H; and, RA3, RB6, and RC10 are all not —H; (3,6,8,10,13-pentasubstituted); or RA1, RA2, and RA4 are all —H; RB5 and RB7 are both —H; RC9, RC10, and RC12 are all —H; and, RA3, RB6, and RC11 are all not —H; (3,6,8,11,13-pentasubstituted).
- 4. A compound according to any one of claims 1 to 3, wherein said nitrogen substituents, RN8 and RN13, are independently C1-4alkyl.
- 5. A compound according to any one of claims 1 to 3, wherein said nitrogen substituents, RN8 and RN13, are not both —Et.
- 6. A compound according to any one of claims 1 to 3, wherein said nitrogen substituents, RN8 and RN13, are independently C1alkyl.
- 7. A compound according to any one of claims 1 to 3, wherein said nitrogen substituents, RN8 and RN13, are independently —Me, —CF3, —CHF2, —CH2F, —CH2OH, or —CH2NH2.
- 8. A compound according to any one of claims 1 to 3, wherein said nitrogen substituents, RN8 and RN13, are both —Me.
- 9. A compound according to any one of claims 1 to 8, wherein each of said ring substituents is independently: halo; ether; ester; acyloxy; oxycarbonyloxy; amido; acylamido; amino; nitro; cyano; azido; or C1-7alkyl.
- 10. A compound according to any one of claims 1 to 8, wherein each of said ring substituents is independently: halo; C1-7alkoxy; ester; acyloxy; oxycarbonyloxy; cyano; or C1-7alkyl.
- 11. A compound according to any one of claims 1 to 8, wherein each of said ring substituents is independently: halo; C1-7alkoxy; ester; acyloxy; oxycarbonyloxy; cyano; unsubstituted C1-7alkyl; C1-7haloalkyl; C1-7hydroxyalkyl; C1-7carboxyalkyl; C1-7acyloxyalkyl; C1-7oxycarbonylalkyl; C1-7oxycarbonyloxyalkyl; C1-7aminoalkyl; C1-7amidoalkyl; C1-7acylamidoalkyl; C1-7cyanoalkyl; or C5-20aryl-C1-7alkyl.
- 12. A compound according to any one of claims 1 to 8, wherein each of said ring substituents is independently:
—F, —Cl, —Br, —I; —OMe, —OEt, —O(nPr), —O(iPr), —O(nBu), —O(tBu), —OCH2Ph; —OCF3, —OCHF2, —OCH2F, —OCCl3, —OCBr3, —OCH2CH2F, —OCH2CHF2, —OCH2CF3; —C(═O)Me, —C(═O)Et, —C(═O)(nPr), —C(═O)(iPr), —C(═O)(nBu), —C(═O)(tBu), —C(═O)Ph; —C(═O)OMe, —C(═O)OEt, —C(═O)O(nPr), —C(═O)O(iPr), —C(═O)O(nBu), —C(═O)O(tBu); —OC(═O)Me, —OC(═O)Et, —OC(═O)(nPr), —OC(═O)(iPr), —OC(═O)(nBu), —OC(═O)(tBu); —OC(═O)OMe, —OC(═O)OEt, —OC(═O)O(nPr), —OC(═O)O(iPr), —OC(═O)O(nBu), —OC(═O)O(tBu); —C(═O)NH2, —C(═O)NHMe, —C(═O)NHEt, —C(═O)NH(nPr), —C(═O)NH(iPr), —C(═O)NH(nBu), —C(═O)NH(tBu), —C(═O)NMe2, —C(═O)NEt2, —C(═O)N(nPr)2, —C(═O)N(iPr)2, —C(═O)N(nBu)2, —C(═O)N(tBu)2; —NHC(═O)Me, —NHC(═O)Et, —NHC(═O)(nPr), —NHC(═O)(iPr), —NHC(═O)(nBu), —NHC(═O)(tBu), —NHC(═O)Ph, succinimidyl, maleimidyl; —NH2, —NHMe, —NHEt, —NH(nPr), —NH(iPr), —NH(nBu), —NH(tBu), —NMe2, —NEt2, —N(nPr)2, —N(iPr)2, —N(nBu)2, —N(tBu)2; —NH(CH2)2NH2, —NH(CH2)3NH2, —NH(CH2)4NH2, —NH(CH2)5NH2, —NH(CH2)6NH2, —NHCH2NH(Me), —NH(CH2)2NH(Me), —NH(CH2)3NH(Me), —NH(CH2)4NH(Me), —NH(CH2)5NH(Me), —NH(CH2)6NH(Me), —NHCH2NH(Et), —NH(CH2)2NH(Et), —NH(CH2)3NH(Et), —NH(CH2)4NH(Et), —NH(CH2)5NH(Et), —NH(CH2)6NH(Et); —NO2; —CN; —N3; —Me, —Et, —nPr, —iPr, —nBu, —tBu; —CF3, —CHF2, —CH2F, —CCl3, —CBr3, —CH2CH2F, —CH2CHF2, —CH2CF3; —CH2OH, —CH2CH2OH, —CH(OH)CH2OH; —CH2COOH, —CH2CH2COOH, —CH2CH2CH2COOH; —CH2OC(═O)Me, —CH2CH2OC(═O)Me, —CH═CHOC(═O)Me; —CH2C(═O)OMe, —CH2CH2C(═O)OMe, —CH═CHC(═O)OMe; —CH2OC(═O)OMe, —CH2CH2OC(═O)OMe, —CH═CHOC(═O)OMe; —CH2NH2, —CH2CH2NH2, —CH═CHNH2, —CH2CH2NMe2; —CH2NHC(═O)Me, —CH2CH2NHC(—O)Me, —CH═CHNHC(═O)Me; —CH2C(═O)NH2, —CH2CH2C(═O)NH2, —CH═CHC(═O)NH2; —CH2CN, —CH2CH2CN, —CH═CHCN.
- 13. A compound according to any one of claims 1 to 8, wherein each of said ring substituents is independently:
—F, —Cl, —Me, —OMe, —CN, —C(═O)OMe, —OC(═O)Me, —OC(═O)OMe, —CH2CH2C(═O)OMe, —CH2CH2OC(═O)Me, —CH═CHC(═O)OMe, —CH═CHOC(═O)Me, —CH═CHC(═O)NH2, —CH═CHC(═O)(morpholin-4-yl), —CH═CHCH2NHC(═O)CF3, —CH═CHCN, or —C≡—CCH2NHC(═O)CF3.
- 14. A compound according to any one of claims 1 to 8, wherein each of said ring substituents is independently: —F, —Cl, —Me, —OMe, —C(═O)OMe, —OC(═O)Me, or —OC(═O)OMe.
- 15. A compound according to any one of claims 1 to 14, wherein the anion is independently derived from one or more of: the following inorganic acids: hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfurous, nitric, nitrous, phosphoric, and phosphorous; the following organic acids: acetic, propionic, succinic, gycolic, stearic, lactic, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetyoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethanesulfonic, ethane disulfonic, oxalic, isethionic, and valeric; and the following polymeric acids: tannic acid, carboxymethyl cellulose.
- 16. A compound according to any one of claims 1 to 14, wherein the anion is independently derived from one or more of: the following inorganic acids: hydrochloric, hydrobromic, hydroiodic; and one of the following organic acids: methanesulfonic, ethanesulfonic, isethionic, fumaric, gluconic.
- 17. A compound according to any one of claims 1 to 14, wherein the anion is independently chloride, bromide, iodide, methylsulfate, ethylsulfate, isethionate, fumarate, or gluconate.
- 18. A compound according to any one of claims 1 to 14, wherein the anion is independently iodide or methylsulfate.
- 19. Compound RHPS01; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 20. Compound RHPS02; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 21. Compound RHPS03; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 22. Compound RHPS04; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 23. Compound RHPS05; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 24. Compound RHPS06; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 25. Compound RHPS07; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 26. Compound RHPS08; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 27. Compound RHPS09; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 28. Compound RHPS10; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 29. Compound RHPS11; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 30. Compound RHPS12; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 31. Compound RHPS13; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 32. Compound RHPS14; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 33. Compound RHPS15; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 34. Compound RHPS16; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 35. Compound RHPS17; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 36. Compound RHPS18; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 37. Compound RHPS19; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 38. Compound RHPS20; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 39. Compound RHPS21; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 40. Compound RHPS22; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 41. A composition comprising a compound according to any one of claims 1 to 40 and a pharmaceutically acceptable carrier or diluent.
- 42. A method of inhibiting telomerase in vitro or in vivo, comprising contacting a cell with an effective amount of compound of the formula:
- 43. A method according to claim 42, wherein RA1 and RA4 are both —H; RB5 and RB7 are both —H; RC9 and RC12 are both —H; and wherein the compound has the following formula:
- 44. A method according to claim 43, wherein:
RA1, RA2, RA3, and RA4 are all —H; RB5, RB6, and RB7 are all —H; and, RC9, RC10, RC11, and RC12 are all —H; (8,13-disubstituted); or RA1, RA2, and RA4 are all —H; RB5, RB6, and RB7 are all —H; RC9, RC10, RC11, and RC12 are all —H; and, RA3 is not —H; (3,8,13-trisubstituted); or RA1, RA2, RA3, and RA4 are all —H; RB5 and RB7 are both —H; RC9, RC10, RC11, and RC12 are all —H; and, RB6 is not —H; (6,8,13-trisubstituted); or RA1, RA2, RA3, and RA4 are all —H; RB5, RB6, and RB7 are all —H; RC9, RC11, and RC12 are all —H; and, RC10 is not —H; (8,10,13-trisubstituted); or RA1, RA2, and RA4 are all —H; RB5 and RB7 are both —H; RC9, RC10, RC11, and RC12 are all —H; and, RA3 and RB6 are both not —H; (3,6,8,13-tetrasubstituted); or RA1, RA2, and RA4 are all —H; RB5, RB6, and RB7 are all —H; RC9, RC11, and RC12 are all —H; and, RA3 and RC10 are both not —H; (3,8,10,13-tetrasubstituted); or RA1, RA2, RA3, and RA4 are all —H; RB5 and RB7 are both —H; RC9, RC11, and RC12 are all —H; and, RB6 and RC10 are both not —H; (6,8,10,13-tetrasubstituted); or RA1, RA2, and RA4 are all —H; RB5 and RB7 are both —H; RC9, RC11, and RC12 are all —H; and, RA3, RB6, and RC10 are all not —H; (3,6,8,10,13-pentasubstituted); or RA1, RA2, and RA4 are all —H; RB5 and RB7 are both —H; RC9, RC10, and RC12 are all —H; and, RA3, RB6, and RC11 are all not —H; (3,6,8,11,13-pentasubstituted).
- 45. A method according to any one of claims 42 to 44, wherein said nitrogen substituents, RN8 and RN13, are independently C1-4alkyl.
- 46. A method according to any one of claims 42 to 44, wherein said nitrogen substituents, RN8 and RN13, are not both —Et.
- 47. A method according to any one of claims 42 to 44, wherein said nitrogen substituents, RN8 and RN13, are independently C1alkyl.
- 48. A method according to any one of claims 42 to 44, wherein said nitrogen substituents, RN8 and RN13, are independently —Me, —CF3, —CHF2, —CH2F, —CH2OH, or —CH2NH2.
- 49. A method according to any one of claims 42 to 44, wherein said nitrogen substituents, RN8 and RN13, are both —Me.
- 50. A method according to any one of claims 42 to 49, wherein each of said ring substituents is independently: halo; ether; ester; acyloxy; oxycarbonyloxy; amido; acylamido; amino; nitro; cyano; azido; or C1-7alkyl.
- 51. A method according to any one of claims 42 to 49, wherein each of said ring substituents is independently: halo; C1-7alkoxy; ester; acyloxy; oxycarbonyloxy; cyano; or C1-7alkyl.
- 52. A method according to any one of claims 42 to 49, wherein each of said ring substituents is independently: halo; C1-7alkoxy; ester; acyloxy; oxycarbonyloxy; cyano; unsubstituted C1-7alkyl; C1-7haloalkyl; C1-7hydroxyalkyl; C1-7carboxyalkyl; C1-7acyloxyalkyl; C1-7oxycarbonylalkyl; C1-7oxycarbonyloxyalkyl; C1-7aminoalkyl; C1-7amidoalkyl; C1-7acylamidoalkyl; C1-7cyanoalkyl; or C5-20aryl-C1-7alkyl.
- 53. A method according to any one of claims 42 to 49, wherein each of said ring substituents is independently:
—F, —Cl, —Br, —I; —OMe, —OEt, —O(nPr), —O(iPr), —O(nBu), —O(tBu), —OCH2Ph; —OCF3, —OCHF2, —OCH2F, —OCCl3, —OCBr3, —OCH2CH2F, —OCH2CHF2, —OCH2CF3; —C(═O)Me, —C(═O)Et, —C(═O)(nPr), —C(═O)(iPr), —C(═O)(nBu), —C(═O)(tBu), —C(═O)Ph; —C(═O)OMe, —C(═O)OEt, —C(═O)O(nPr), —C(═O)O(iPr), —C(═O)O(nBu), —C(═O)O(tBu); —OC(═O)Me, —OC(═O)Et, —OC(—O)(nPr), —OC(═O)(iPr), —OC(═O)(nBu), —OC(═O)(tBu); —OC(═O)OMe, —OC(═O)OEt, —OC(═O)O(nPr), —OC(═O)O(iPr), —OC(═O)O(nBu), —OC(═O)O(tBu); —C(═O)NH2, —C(═O)NHMe, —C(═O)NHEt, —C(═O)NH(nPr), —C(═O)NH(iPr), —C(═O)NH(nBu), —C(═O)NH(tBu), —C(═O)NMe2, —C(═O)NEt2, —C(═O)N(nPr)2, —C(═O)N(iPr)2, —C(═O)N(nBu)2, —C(═O)N(tBu)2; —NHC(═O)Me, —NHC(═O)Et, —NHC(═O)(nPr), —NHC(═O)(iPr), —NHC(═O)(nBu), —NHC(═O)(tBu), —NHC(═O)Ph, succinimidyl, maleimidyl; —NH2, —NHMe, —NHEt, —NH(nPr), —NH(iPr), —NH(nBu), —NH(tBu), —NMe2, —NEt2, —N(nPr)2, —N(iPr)2, —N(nBu)2, —N(tBu)2; —NH(CH2)2NH2, —NH(CH2)3NH2, —NH(CH2)4NH2, —NH(CH2)5NH2, —NH(CH2)6NH2, —NHCH2NH(Me), —NH(CH2)2NH(Me), —NH(CH2)3NH(Me), —NH(CH2)4NH(Me), —NH(CH2)5NH(Me), —NH(CH2)6NH(Me), —NHCH2NH(Et), —NH(CH2)2NH(Et), —NH(CH2)3NH(Et), —NH(CH2)4NH(Et), —NH(CH2)5NH(Et), —NH(CH2)6NH(Et); —NO2; —CN; —N3; —Me, —Et, —nPr, —iPr, —nBu, —tBu; —CF3, —CHF2, —CH2F, —CCl3, —CBr3, —CH2CH2F, —CH2CHF2, —CH2CF3; —CH2OH, —CH2CH2OH, —CH (OH)CH2OH; —CH2COOH, —CH2CH2COOH, —CH2CH2CH2COOH; —CH2OC(═O)Me, —CH2CH2OC(═O)Me, —CH═CHOC(═O)Me; —CH2C(═O)OMe, —CH2CH2C(═O)OMe, —CH═CHC(═O)OMe; —CH2OC(═O)OMe, —CH2CH2OC(═O)OMe, —CH═CHOC(═O)OMe; —CH2NH2, —CH2CH2NH2, —CH═CHNH2, —CH2CH2NMe2; —CH2NHC(═O)Me, —CH2CH2NHC(═O)Me, —CH═CHNHC(═O)Me; —CH2C(═O)NH2, —CH2CH2C(═O)NH2, —CH═CHC(═O)NH2; —CH2CN, —CH2CH2CN, —CH═CHCN.
- 54. A method according to any one of claims 42 to 49, wherein each of said ring substituents is independently:
—F, —Cl, —Me, —OMe, —CN, —C(═O)OMe, —OC(═O)Me, —OC(═O)OMe, —CH2CH2C(═O)OMe, —CH2CH2OC(═O)MAe, —CH═CHC(═O)OMe, —CH═CHOC(═O)Me, —CH═CHC(═O)NH2, —CH═CHC(═O)(morpholin-4-yl), —CH═CHCH2NHC(═O)CF3, —CH═CHCN, or —C═CCH2NHC(═O)CF3.
- 55. A method according to any one of claims 42 to 49, wherein each of said ring substituents is independently: —F, —Cl, —Me, —OMe, —C(═O)OMe, —OC(═O)Me, or —OC(═O)OMe.
- 56. A method according to any one of claims 42 to 55, wherein the anion is independently derived from one or more of: the following inorganic acids: hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfurous, nitric, nitrous, phosphoric, and phosphorous; the following organic acids: acetic, propionic, succinic, gycolic, stearic, lactic, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetyoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethanesulfonic, ethane disulfonic, oxalic, isethionic, and valeric; and the following polymeric acids: tannic acid, carboxymethyl cellulose.
- 57. A method according to any one of claims 42 to 55, wherein the anion is independently derived from one or more of: the following inorganic acids: hydrochloric, hydrobromic, hydroiodic; and one of the following organic acids: methanesulfonic, ethanesulfonic, isethionic, fumaric, gluconic.
- 58. A method according to any one of claims 42 to 55, wherein the anion is independently chloride, bromide, iodide, methylsulfate, ethylsulfate, isethionate, fumarate, or gluconate.
- 59. A method according to any one of claims 42 to 55, wherein the anion is independently iodide or methylsulfate.
- 60. A method according to claim 42, wherein the compound is selected from compound RHPS01; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 61. A method according to claim 42, wherein the compound is selected from compound RHPS02; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 62. A method according to claim 42, wherein the compound is selected from compound RHPS03; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 63. A method according to claim 42, wherein the compound is selected from compound RHPS04; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 64. A method according to claim 42, wherein the compound is selected from compound RHPS05; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 65. A method according to claim 42, wherein the compound is selected from compound RHPS06; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 66. A method according to claim 42, wherein the compound is selected from compound RHPS07; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 67. A method according to claim 42, wherein the compound is selected from compound RHPS08; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 68. A method according to claim 42, wherein the compound is selected from compound RHPS09; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 69. A method according to claim 42, wherein the compound is selected from compound RHPS10; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 70. A method according to claim 42, wherein the compound is selected from compound RHPS11; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 71. A method according to claim 42, wherein the compound is selected from compound RHPS12; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 72. A method according to claim 42, wherein the compound is selected from compound RHPS13; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 73. A method according to claim 42, wherein the compound is selected from compound RHPS14; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 74. A method according to claim 42, wherein the compound is selected from compound RHPS15; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 75. A method according to claim 42, wherein the compound is selected from compound RHPS16; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 76. A method according to claim 42, wherein the compound is selected from compound RHPS17; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 77. A method according to claim 42, wherein the compound is selected from compound RHPS18; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 78. A method according to claim 42, wherein the compound is selected from compound RHPS19; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 79. A method according to claim 42, wherein the compound is selected from compound RHPS20; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 80. A method according to claim 42, wherein the compound is selected from compound RHPS21; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 81. A method according to claim 42, wherein the compound is selected from compound RHPS22; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
- 82. A method of regulating cell proliferation in vitro or in vivo, comprising contacting a cell with an effective amount of compound as described in any one of claims 42 to 81.
- 83. A method of regulating cell proliferation, comprising contacting a cell with an effective amount of an active compound as described in any one of claims 42 to 81, in vitro or in vivo.
- 84. A method of treating a proliferative condition in a subject comprising administering to said subject a therapeutically-effective amount of a compound as described in any one of claims 42 to 81, in vitro or in vivo.
- 85. A method of treating cancer in a subject comprising administering to said subject a therapeutically-effective amount of a compound as described in any one of claims 42 to 81, in vitro or in vivo.
- 86. A compound as described in any one of claims 42 to 81 for use in a method of treatment of the human or animal body.
- 87. A compound as described in any one of claims 42 to 81 for use in a method of treatment of a proliferative condition of the human or animal body.
- 88. A compound as described in any one of claims 42 to 81 for use in a method of treatment of cancer of the human or animal body.
- 89. Use of a compound as described in any one of claims 42 to 81 for the manufacture of a medicament for use in the treatment of a proliferative condition.
- 90. Use of a compound as described in any one of claims 42 to 81 for the manufacture of a medicament for use in the treatment of cancer.
RELATED APPLICATION
[0001] This application claims priority to U.S. Provisional Application No. 60/239,267 filed Oct. 12, 2000, the contents of which are incorporated herein by reference in their entirety.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/GB01/04557 |
10/12/2001 |
WO |
|